GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT will be speaking at the 'Translation and Innovation in induced Pluripotent Stem Cell Science' Workshop at Saïd Business School, Oxford on the 11th February 2020 and at the RESTORE meeting in Berlin on the 17th February 2020.
Osaka University transplants iPS cell-based heart cells in world's first clinical trial
Osaka University transplants iPS cell-based heart cells in world's first clinical trial | The Japan Times
An Osaka University team said it has carried out the world's first transplant of cardiac muscle cells created from iPS cells in a physician-initiated ...
Who would have thought 5 years ago that GSK, BMS, Gilead, Pfizer, Roche, J&J, Takeda, Astellas, Vertex... - will become the major cell-gene therapy companies? The craze for acquisitions will continue in 2020. Pharma/Biotech will eat them all!
Thanks to all who participated in the iPSC Quality Round Data Discussion calls this week! Minutes will be sent out Monday.
A Quality Round update was just sent to Participants. We remind those doing retests to upload the data template sheets in addition to raw data.
Tokyo's Heartseed reaps $26M to test its iPS cell injections for heart failure - The company forms spherical clusters of heart cells from purified, allogeneic iPSCs, which are injected into the heart muscle wall.
We are very grateful for @NIBSC_MHRA, @MCRI_for_kids, @yposkesi, @nyscf, @Inserm, and @cmrb for joining the first two Quality Round data discussion calls today. Your comments and feedback have been documented.
GAiT just sent an iPSC Quality Round Update to Participants from 18 sites across 11 countries informing them of the status of Quality re-tests, the data workshop, and manuscript preparation.
Kyoto University seeks government approval to conduct a clinical trial of transplanted cartilage made from iPS cells -
Kyoto Univ. seeks to use stem cells for damaged knee joint treatment
Kyoto University says it has asked for government approval to conduct a clinical trial of transplanting cartilage made from induced pluripotent stem c...